Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-03-17

Clinical Trial Update: Safety Study of Abatacept to Treat Refractory Sarcoidosis [Phase 2]

View source ↗

Summary

Phase II safety study of abatacept for refractory sarcoidosis was terminated; results posted but no new efficacy data highlighted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Abatacept (abatacept)

Snippet

Sponsor: University of Chicago | Conditions: Sarcoidosis | Phase 2 | Status: TERMINATED | Results posted: 2020-03-17